Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19

Repurposing Existing Medicines Is Key Part Of Pandemic Solution, Industry Insists

Executive Summary

Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.

You may also be interested in...



Repurposing Initiatives Proposed To Unlock ‘Untapped Potential’ In Europe

Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.

Sandoz Maintains Lead On Denosumab As It Files With FDA

Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.

Advanz Agrees Multi-Market Omalizumab Deal With Alvotech

Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel